#	Pagina
attuale pagina	/open-h2020/projects/217180/index.html

Opendata, web and dolomites

KHON2bTREAT SIGNED

Late Clinical Development of KH176: an innovative orphan drug to reach mitochondrial disease patients & market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

KHON2bTREAT project word cloud

Explore the words cloud of the KHON2bTREAT project. It provides you a very rough idea of what is the project "KHON2bTREAT" about.

lucrative 250 chronic approximately cagr 2022 trial follows drug 2a modulator investor projected population dutch diseases excl fast addressable 2012 licensing generics mitochondrial spin 25 entrepreneurs care forms clinical rare perform 2024 35m 2b authorization return progression melas kh176 market designed treat cumulative 2000 worldwide patients entering ema sme eic grant proprietary revert times khondrion 209b base instrument cure redox 4 midd patient exclusivity designation khon2btreat reaching devoted orphan adult group stall parkinson 11 medicine preclinical operates genetic data bv few progressive drugs prescription 6 financing co molecule gt risk dysfunction milestones disease patent exists niche first indications 21 cellular expedited disorders sales fda approval small corrects smes revenue portfolio dose complaints broad

Project "KHON2bTREAT" data sheet

The following table provides information about the project.

Coordinator	KHONDRION BV Organization address address: VAN HEEMSTRAWEG 49 E city: BEUNINGEN postcode: 6641 AA website: http://www.khondrion.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.khondrion.com/about-us/
Total cost	3˙337˙525 €
EC max contribution	2˙336˙267 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-10-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KHONDRION BV KHONDRION BV Organization address address: VAN HEEMSTRAWEG 49 E city: BEUNINGEN postcode: 6641 AA website: http://www.khondrion.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (BEUNINGEN)	coordinator	2˙336˙267.00

Map

Project objective

Mitochondrial diseases are chronic progressive disorders for which no cure exists, affecting approximately 250,000 patients worldwide. KH176 is a proprietary small molecule designed by the Dutch SME Khondrion BV to treat a large group of rare mitochondrial and related diseases. With KH176, a new redox-modulator, Khondrion aims to stall disease progression and revert clinical complaints in mitochondrial diseases; it corrects cellular consequences of mitochondrial dysfunction and has broad market potential. Khondrion’s management has >25 years experience in mitochondrial medicine, patient care and drug development, and is supported by highly experienced entrepreneurs. Since 2012, Khondrion completed preclinical, Phase 1&2a clinical, EMA&FDA orphan drug designation providing market exclusivity, and has a strong patent portfolio. Khondrion operates in a small but highly lucrative niche market. The addressable market for KH176 is 50,000-250,000 mitochondrial disease patients in Europe&US. Base-case cumulative revenue on KH176 is expected €35M by 2024, a return of >10 times this grant. Worldwide orphan drug sales are to increase at 11% CAGR to $209b in 2022; orphan drugs are projected to account for 21.4% of worldwide prescription sales by 2022 (excl. generics) from 6% in 2000. Worldwide, Khondrion is one of few SMEs devoted to develop a drug for mitochondrial diseases. Khondrion follows fast, risk-reduced development for KH176; first market approval in adult patients (MELAS/MIDD), entering expedited authorization for other mitochondrial diseases. As spin-out, Khondrion aims licensing KH176 for major indications (preclinical data on KH176 in genetic forms of Parkinson’s completed). Financing of this KHON2bTREAT project by the EIC SME instrument Phase 2 will enable Khondrion to perform the dose-finding clinical trial (Phase 2b) on KH176 in its patient population, reaching essential milestones for investor/co-development financing of the Phase 3 trial for market approval.

Deliverables

List of deliverables.
Dissemination material	Websites, patent fillings, videos etc.	2020-01-14 14:59:05
Press releases and information papers on KHON2bTREAT to relevant stakeholders	Websites, patent fillings, videos etc.	2020-01-14 14:49:17

Take a look to the deliverables list in detail: detailed list of KHON2bTREAT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KHON2BTREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KHON2BTREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More

PRIVATETRACK (2019)

PRIVATETRACK: Privacy-friendly, low-power intelligent room occupancy detection and people counting.

Read More

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More